Business
Galmed Pharmaceuticals Announces Publication in "The Journal of Autoimmunity" for its IND ready, Amilo-5MER, a specific anti-inflammatory compound
- Amilo-5MER suppresses chronic inflammations in broad spectrum of animal models of inflammatory diseases. - Amilo-5MER has a unique mechanism of action
About this update from Galmed Pharmaceuticals Ltd.
[{"type":"text","content":"- Amilo-5MER suppresses chronic inflammations in broad spectrum of animal models of inflammatory diseases.\n - Amilo-5MER has a unique mechanism of action targeting Serum Amyloid A (SAA) associated pathologies, i.e, chronic inflammatory conditions.\n\n\nTEL AVIV, Israel, Aug. 19, 2021 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) (\"Galmed\" or the \"Company\"), a clinical-stage biopharmaceutical company for liver, metabolic and inflammatory diseases announced today the publication in The Journal of Autoimmunity for its IND ready compound, Amilo-5MER entitled: \"MTADV 5-MER peptide suppresses chronic inflammations as well as autoimmune pathologies and unveils a new potential target-Serum Amyloid A.\"\nAmilo-5MER, is a five amino acid in a specific sequence that was originally isolated from synovial fluid of rheumatoid arthritis (RA) patients. This human peptide displays an efficient anti-inflammatory effect to ameliorate pathology and clinical symptoms in mouse models of RA, inflammatory bowel disease (IBD) and multiple sclerosis (MS). The presumed MoA by which Amilo-5MER affects chronic inflammation is binding to SAA and preventing its ability to activate immune cells for pro inflammatory cytokine secretion. \nStudies have demonstrated that Amilo-5MER significantly inhibits the release of pro-inflammatory cytokines IL-6 and IL-1β from SAA activated human fibroblasts, THP-1 monocytes and peripheral blood mononuclear cells. Amilo-5MER suppresses the pro-inflammatory IL-6 release from SAA-activated cells, but not from non-activated cells providing selective anti inflammatory properties. \nProf. David Naor, a winner of 2021 Kaye Prize for scientific innovation and affiliated with the Lautenberg Center of Immunology and Cancer Research, Faculty of Medicine, Hebrew University of Jerusalem, Israel and the inventor of Amilo-5MER commented \"Serum Amyloid A (SAA) initiates and activates the cascade of events leading to chronic inflammation by stimulating release of the pro-inflammatory cytokines IL-6,IL-1β and TNFα, generating a \"cytokine storm\" and subsequently damage to the body tissues. Amilo-5MER, specifically binds to subunits of SAA, thereby neutralizing its pathological structure and consequently its ability to stimulate \"cytokine storm\", thus interfering with the inflammatory process. Challenged by the unmet nee...